Table 1. Baseline patient characteristics.
| Characteristic | Arm A: Metformin alone | Arm B: Metformin with Rapamycin |
|---|---|---|
| n = 11 | n = 11 | |
| Age-years | ||
| median | 58 | 66 |
| range | 34–73 | 52–72 |
| Sex-no. (%) | ||
| female | 6 (55) | 4 (36) |
| male | 5 (45) | 7 (64) |
| Race-no. (%) | ||
| white | 10 (91) | 11 (100) |
| black | 1 (9) | 0 |
| other | 0 | 0 |
| ECOG performance status-no. (%)1 | ||
| 0 | 2 (18) | 2 (18) |
| 1 | 9 (82) | 9 (82) |
| Tumor location-no. (%) | ||
| head | 7 (64) | 4 (36) |
| body | 2 (18) | 4 (36) |
| tail | 1 (9) | 3 (27) |
| unspecified | 1 (9) | 0 |
| Metastatic site-no. (%) | ||
| liver only | 6 (55) | 3 (27) |
| lung only | 0 | 1 (9) |
| other/multiple | 5 (45) | 7 (64) |
| Histology-no. (%) | ||
| well/moderately differentiated | 2 (18) | 5 (45) |
| poorly differentiated | 7 (64) | 2 (18) |
| other/unknown | 2 (18) | 4 (36) |
| Carbohydrate Antigen 19-9-U/mL | ||
| median | 46.7 | 23.4 |
| range | 10.3–586.5 | 3.8–218.1 |
| Prior FOLFIRINOX-no. (%) | ||
| yes | 6 (55) | 5 (45) |
| no | 5 (45) | 6 (55) |
| Time since first diagnosis-months | ||
| median | 11 | 13 |
| range | 6.7–43.4 | 5.6–46.7 |
| Prior systemic therapies-no. (%) | ||
| 1 | 7 (64) | 7 (64) |
| 2 | 2 (18) | 4 (36) |
| 3 | 1 (9) | 0 |
| ≥ 4 | 1 (9) | 0 |
1ECOG, Eastern Cooperative Oncology Group.